GSK’s mR­NA flu shot is head­ing to Phase 3; Sum­mit’s $235M of­fer­ing

Plus, news about Oru­ka Ther­a­peu­tics, Centes­sa, Take­da, In­nate Phar­ma and Liq­uidia:

GSK’s mR­NA flu vac­cine suc­ceeds against both strains in Phase 2: The phar­ma com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER